Biologics in Pharmaceuticals: Manufacturing, Quality, and Regulatory Framework
Biologics are large, complex molecules produced using living cells. They include a range of therapeutic products such as:Click to read the full article.
Biologics
Biologics Instability and Aggregation Issues? Practical Controls and Solutions
Identifying the symptoms of instability and protein aggregation is crucial for early intervention. Common signals include:Click to read the full article.
Biologic subvisible particles OOS during stability pull at 3/6/12 months: investigation strategy aligned to FDA/EMA expectations and comparability principles
The first step in addressing OOS results is to clearly define the symptoms or signals indicating that an issue may exist. Common signals in the lab or production area for…
Biologic viral clearance validation gap after upstream media/raw material change: patient safety impact assessment and batch disposition governance
Identifying the early signals of a biologic viral clearance validation gap is critical to swift action. Symptoms may manifest as:Click to read the full article.
Biologic cold chain excursion impact during PPQ / process validation: investigation strategy aligned to FDA/EMA expectations and comparability principles
Recognizing early indications of cold chain excursions is essential for timely interventions. Symptoms may manifest as deviations in physical properties, atypical test results, or unusual complaints from stakeholders. Common signals…
Biologic host cell protein (HCP) OOS after single-use system supplier change: viral safety and contamination response plan with inspection-ready evidence
Identifying the symptoms or signals that indicate a potential OOS situation is critical for the initial response. In the context of HCP testing following a supplier change in single-use systems,…
Biologic residual DNA OOS during deviation investigation board review: single-use systems risk controls, leachables review, and supplier oversight actions
Identifying symptoms and signals indicative of issues with residual DNA levels in biologics often begins with alerts from routine quality control assays. Common signals include:Click to read the full article.
Biologic endotoxin OOS during deviation investigation board review: data integrity checks for bioassays and analytical similarity packages
The first step in managing an OOS result is to identify the symptoms or signals present in the manufacturing environment. For biologic endotoxin testing, the following indicators might suggest potential…
Biologic stability failure (real-time/accelerated) during commercial manufacturing campaign: investigation strategy aligned to FDA/EMA expectations and comparability principles
Recognizing the symptoms of a biologic stability failure is paramount to initiating a timely investigation. Common signals include:Click to read the full article.
Biologic cell culture contamination event during deviation investigation board review: how to justify rework/reprocessing vs rejection for biologic lots
Identifying the initial signals of cell culture contamination is imperative. Symptoms may come from various sources, including in-process observations, laboratory data alerts, or complaints from production staff. Common indicators include:Click…
Biologic container closure integrity failure during downstream purification scale-up: how to justify rework/reprocessing vs rejection for biologic lots
Recognizing the symptoms of container closure integrity failures is the first step in addressing the problem. Common indicators may vary based on operations but generally include:Click to read the full…
Biologic bioburden excursion pre-sterile filtration after single-use system supplier change: investigation strategy aligned to FDA/EMA expectations and comparability principles
Identifying the symptoms of a bioburden excursion early is critical for containment and investigation. Signs may include:Click to read the full article.